They reported that subgroups of patients with HNSCC, who may achieve increased benefit from afatinib, were identified based on prespecified tumor biomarkers (i.e., HPV‐negative, EGFR amplification, low HER3 expression, and high PTEN expression (Cohen et al., 2017). This evidence concerns the gene PTEN and neoplasm.